Latest News
MaaT Pharma receives negative CHMP trend vote for MaaT013
15 September 2026 - Clinical-stage biotechnology company MaaT Pharma (Euronext Paris:MAAT) disclosed on Tuesday that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a negative trend opinion ...
GSK to acquire trispecific T cell-engager from Chimagen for multiple myeloma
15 September 2026 - Biopharmaceutical company GSK plc (LON:GSK) (NYSE:GSK) announced on Tuesday that it has agreed to acquire a potential best-in-class trispecific T cell-engager (TCE) from privately held biotechnology company Chimagen Biosciences.Th...
FDA approves Scholar Rock's ISEMBYLD to treat spinal muscular atrophy
15 September 2026 - Cure SMA, a nonprofit organisation supporting those impacted by spinal muscular atrophy (SMA), on Monday welcomed the announcement by biopharmaceutical company Scholar Rock (NASDAQ:SRRK) of FDA approval of ISEMBYLD (apitegromab-ms...
PSMA Connect partners with HealthIQ Solutions
15 September 2026 - PSMA Connect, a Healthcare Group Purchasing Organisation (GPO), and HealthIQ Solutions, a provider of remote patient care management and clinical technology, said on Monday that they have formed a new strategic provider alliance.T...
Kelun-Biotech publishes phase III data for trastuzumab botidotin in HER2-positive breast cancer
14 September 2026 - Chinese biopharmaceutical company Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (HKG: 6990) on Monday announced that it has published phase III results for its HER2-targeted antibody–drug conjugate trastuzumab botidotin ...